Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01622582
First received: June 15, 2012
Last updated: March 2, 2015
Last verified: March 2015
  Purpose

Engraftment Syndrome after Autologous Stem Cell Transplant: Retrospective Review in Patients with Multiple Myeloma


Condition
Multiple Myeloma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by University of Arkansas:

Primary Outcome Measures:
  • number of patients developing Engraftment syndrome following stem cell transplant [ Time Frame: 6 months post-transplant ] [ Designated as safety issue: Yes ]
    A retrospective review where subjects medical records are studied for development of engraftment syndrome 6 months after stem cell transplant


Enrollment: 796
Study Start Date: January 2006
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Detailed Description:

A retrospective chart review series will be performed fpr subjects enrolled from 1/1/2006.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with Multiple Myeloma, developing engraftment syndrome

Criteria

Inclusion Criteria:

  • Patients with Multiple Myeloma, developing engraftment syndrome

Exclusion Criteria:

  • Patients with Multiple Myeloma, with no features of engraftment syndrome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01622582

Locations
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Senu Apewokin, MD UAMS
  More Information

No publications provided

Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT01622582     History of Changes
Other Study ID Numbers: UARK 2008-30
Study First Received: June 15, 2012
Last Updated: March 2, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Arkansas:
Multiple Myeloma, Engraftment syndrome

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases

ClinicalTrials.gov processed this record on July 28, 2015